The primary objective of this initial clinical trial is to evaluate safety and immune responses of three different dose levels and two different vaccination schedules of ARCT-2304 vaccine. Immune ...

Pomalidomide is under clinical development by Qilu Pharmaceutical and currently in Phase III for Refractory Multiple Myeloma.